Moleculin Biotech (NASDAQ:MBRX) Issues Quarterly Earnings Results

Moleculin Biotech (NASDAQ:MBRX) released its earnings results on Thursday. The company reported ($3.54) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($1.85), FiscalAI reports.

Moleculin Biotech Stock Performance

Shares of MBRX opened at $2.20 on Friday. Moleculin Biotech has a 1 year low of $1.79 and a 1 year high of $25.00. The company has a market cap of $11.75 million, a price-to-earnings ratio of -0.07 and a beta of 1.74. The firm has a fifty day moving average of $2.34 and a 200-day moving average of $4.74.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moleculin Biotech currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.